DIMENSION @_DimensionCap
Dimension is a multistage, research oriented, investment firm partnering with companies across the frontiers of science and compute dimensioncap.com New York and San Francisco Joined June 2022-
Tweets416
-
Followers3K
-
Following25
-
Likes1K
For large pharma companies serious about integrating ML throughout their organizations, I believe they'll need infrastructure like what @tamarindbio has created. With so many open and closed source solutions, a constantly changing model backdrop, pipelines that need constructing/maintaining/provisioning, etc ~ it's only going to get harder to conquer without a partner like Tamarind.
We’re proud to share that @tamarindbio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models
every year @newlimit, we host friends at the lab & share our progress for 2026, we announced: - 2X increase in discovery rates with AI systems - new program for endothelial cells - 0 -> 1 medicines headed to the clinic - accelerating recovery from alcohol some highlights --
Congrats to Deniz, Sherry and @tamarindbio team on the partnership with Lilly! Excited to announce that Lilly's TuneLab model initiative will be solely powered by Tamarind's platform. There are more high performance open and closed-source bio ML models now than ever. Tamarind has built the leading hosting and inference infrastructure to coordinate these models and run them in production for some of the largest Pharma companies in the world. Great milestone deal here and exciting times ahead. 🚀
We’re proud to share that @tamarindbio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models
2 years ago Chai was a small team led by @joshim5 & @jackdent working out of the Dimension offices today they are leading the charge to reinvigorate western pharma and biotech. Lilly and Pfizer are partners. the majority of pharma queuing up.. the rate of progress: staggering
Today we’re launching @chaidiscovery, led by @joshim5 & his polymathic world class cofounders. We’re also open sourcing Chai-1: a state of the art frontier model for biomolecular interactions. @_DimensionCap has co-led the founding round alongside Thrive & OpenAI
we are all underrating the second & third order effects of biologic design costs going to ~$0 congratulations to the chai team!
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
It's been amazing to watch @joshim5, @jackdent, and team work at speed. This is the wrong time to be a goalpost mover or a chronic under-estimator of ML velocity, and my team at @_DimensionCap would agree. Chai is speed-running what I thought would take years and years. I'm asking myself all sorts of new questions now, mostly about what would be possible if biologic design cost/time asymptotes towards 0. Today, I still think folks are not thinking creatively enough about what happens here. From having immediate/potent tool compounds, to mechanistic deconvolution, to reagents that actually work without dressing up Western blots in MS paint. Oh, and amazing therapeutics too. The sky is the limit!
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
New Limit just raised $435 million. This is, in part, because they've had a massive breakthrough on reversing the age of the liver with their new brand of genetic reprogramming drugs. For the first time, NewLimit's co-founder and president Jacob Kimmel details the company's breakthrough here. We also get into the longevity and bio-tech fields more broadly to explain where aging science and AI are heading. If nothing else, come to see some mice get drunk. The Core Memory podcast is available wherever you pod, and I'll put the YouTube link down below in the replies. Our show is sponsored by Brex and SendCutSend. They are both wise and benevolent. Timestamps 0:00 Intro 3:50 What Is Epigenetic Reprogramming? 7:16 Growing a Whole Animal From One Old Cell 13:06 Meet Ambrosia, the AI Hunting for Youth 22:44 $435 Million and the Race to Human Trials 29:26 The Drunk Mice That Skip the Hangover 36:48 Inside the First Human Trial 43:14 Will There Ever Be a Hangover Pen? 49:39 Beyond the Liver: The Delivery Problem 1:03:27 Answering the Skeptics 1:12:42 Will OpenAI Become a Drug Company? 1:23:53 The Health Story Bigger Than AI? 1:35:00 How Far Behind Is the US vs China? 1:53:10 Can We Build Computers From Neurons?
📣 New @_DimensionCap essay on training data recipes for bio-focused ML models, by @bauer_lesavage The data market is pretty vibrant right now. Frontier labs are buying big chunks of targeted data, multi-modal data, even bio-data. Bio platform companies are benefitting from this obviously ~ it's a new (and large) customer segment for them beyond pharma. With this marketplace developing, I was happy that Bauer chose to explore this topic. He makes arguments around data scale versus data quality, semantic versus stylistic diversity, amongst other things. While there's a good bit of model training theory from LLMs that ports over to life-sci, Bauer found it's definitely not 1:1. Like all things, there's some nuance. Check out his newest paper!
great to see GLUE (@MonteRosaTx) get a very well deserved call out today as they pioneer in designing drugs that have potential to help millions of lives across onc and i&i whilst unlocking new classes of mechanisms and modalities
Dimension has co-led a $100M financing into @MonteRosaTx. Thrilled to support @markus_warmuth and the entire team at the cutting edges of geometric deep learning, next gen proteomics, and molecular glue degraders.
it’s a bad day to be an aging cell
almost exactly 3 years ago Dimension led a $40M Series A in @newlimit, inspired by the pioneering vision of @jacobkimmel @byersblake and @brian_armstrong. today, we announce a $435M Series C led by Founders Fund w Thrive and Greenoaks as new partners. lets go chart the future.
I love supporting cool and meaningful science, especially when it's being driven by a team with infinite ambition. @newlimit is just that!
Following breakthrough results, we’re bringing longevity medicine to human trials. We’ve raised a $435M Series C led by @foundersfund to make it happen. Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.
on day 1 @newlimit, we imagined it would take 10+ years to invent real medicines. our recent results have accelerated the timeline to next year. we've raised a Series C led by @foundersfund alongside @ThriveCapital, @Greenoaks, and many others to bring therapies to the clinic. medicines for aging are among the most valuable possible technologies. we are grateful to our partners for the opportunity to pursue this mission.
Following breakthrough results, we’re bringing longevity medicine to human trials. We’ve raised a $435M Series C led by @foundersfund to make it happen. Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.
Following breakthrough results, we’re bringing longevity medicine to human trials. We’ve raised a $435M Series C led by @foundersfund to make it happen. Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.
almost exactly 3 years ago Dimension led a $40M Series A in @newlimit, inspired by the pioneering vision of @jacobkimmel @byersblake and @brian_armstrong. today, we announce a $435M Series C led by Founders Fund w Thrive and Greenoaks as new partners. lets go chart the future.
Today we're announcing that @_DimensionCap has led the $40M Series A of @newlimit alongside @foundersfund and @kleinerperkins!! techcrunch.com/2023/05/16/new…
Dimension has doubled down in each of the last 3 financings @bernhardsson @akshat_b and team are assembling the absolute best of the best of infra x computer science builders engineering the requisite infra to accelerate AI across every major column of the global GDP LFG
we are stage agnostic and invest large capital in a small number of companies across the frontiers of compute (silicon through infra) and science (biotech through physics). in no particular order, non exhaustive: Chai (first outside capital, coled seed) NewLimit (led the A, first outside capital) Anthropic (by way of neolab Coefficient, which we cofounded) Earendil (coled series C with DST in US and Shanghai) Monte Rosa ($GLUE, coled and structured an overnight offering in 2024 with Baker Bros. per 13f's we're now a top 3 holder) Odyssey ($ODTX, led the crossover, coanchored IPO) Modal (have invested in the last 3 rounds) Aspect (bioprinting human tissue, led series B in Vancouver) Achira (physics based neolab we cofounded) Axiom (last 2 rounds) stealth cos we can't yet disclose ... others we prefer to spend depthful time with the founders we back and come in with a research led mentality: a prepared mind. consensus rarely excites us and we're most comfortable in small groups - often even in isolation. we sometimes publish some of our research here: research.dimensioncap.com our team is small, concentrated as is our portfolio: @nanli @AGoulburn @SimonDBarnett @nikhilvnamburi @bauer_lesavage @hathwar607 @ChemVagabond
@zavaindar @_DimensionCap Is the full portfolio public? Would love to see how your deep science/compute research thesis translates into your other ecosystem bets.
We're partnering with an up-and-coming startup called @AnthropicAI for this. I'm bullish – I think they could be big one day!
Modal is proud to now support @claudeai Managed Agents with Modal Sandboxes.
awesome to see two of our largest portfolio positions at @_DimensionCap, Anthropic and Modal, partner w sandboxes for managed agents
Modal is proud to now support @claudeai Managed Agents with Modal Sandboxes.
Great post from @Convokebio mapping out the wide set of opportunities that exist in drug discovery. Most have no or suboptimal treatments, so much opportunity to develop medicines that impact patients!
Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems convoke.bio/blog/introduci…
Chelsey Zhao @ChelseyZhao777
1 Followers 95 Following Building the AI brain for new materials in energy|phd@mineral physics|startup@ai4s&industry
Chengcheng Zhao @Chelsey_Zhao
0 Followers 5 Following
Avak Kahvejian @AvakK
964 Followers 950 Following Partner @flagshippioneer VentureLabs. Scientist, Innovator and Entrepreneur working at the intersection of #Biology #Technology #Medicine
Aury Cifuentes @cifuentweets
379 Followers 2K Following ✨Actively investing in female-led teams at How Women Invest ☀️ Ex- @plugandplaytc and built stuff @business. Views are my own
madhav @Madhav_goyal_
4K Followers 6K Following breaking evals @cerebral_system infra @campnetworkxyz | gap life @IEuniversity
Michelle Weiss @pivoteightllc
1 Followers 93 Following
anika @anikamirzaa
731 Followers 768 Following host @getthecheckpod, @sierraplatform // @kalshi trading bonus at the link
Uncle Sam @genome_seq
3 Followers 223 Following
SB @Grothendiecktr
42 Followers 593 Following
Nazanin Soltan @nazzzsoltan
178 Followers 444 Following
Sylvain Gariel @SylvainGariel
1K Followers 2K Following Building at the intersection of AI for Science and Drug Discovery. Based in San Francisco. Venture Partner @Frst_vc
Michael Myles @UseYourNews
210 Followers 3K Following ✝️ @UChicago ‘29 | Supercharge your AI agents with @SemanticReach | https://t.co/1GxhonHy3v
Julia Seregina @julia_in_purple
159 Followers 560 Following Building something new in human x AI interaction. Fellow @southpkcommons F25
brn @brnjan
29 Followers 202 Following
Dave Goldman @dgoldzz
3K Followers 4K Following Currently testing a harness for agentic trading. Prev. Index, equity, and treasuries derivatives market maker Prev. CEO @Eliqs, @BarrelDAO Prev. GP GHI Fund
Maninjay Atianand @atianand_lab
484 Followers 375 Following building something new. ex. asst prof @PittTweet | #RNA #microprotein #biotech
Tamer Mohamed @_tamerm
1K Followers 209 Following Dad, husband, bioengineer and entrepreneur. Founder and CEO of @aspectbiosys.
Krithik @SaiSreenish
255 Followers 3K Following
hinata_ji @yours_ex_bf
8 Followers 363 Following comp bio | building things trying to write on : https://t.co/sp8H5nMxHc
Martin Cox @TheRealMartinCx
10 Followers 42 Following
Aryan @AryanGo54280959
95 Followers 2K Following Computer Engineering student 👨🎓 @NCSSM alum RTL, FPGA, ASIC
Lorenzo Bini @LorenzoBini47
37 Followers 322 Following PhD Candidate at @unige_en working on GenAI for Biology | GraphML | @CarnegieMellon
Harry @HarryHH1993
519 Followers 2K Following ⚔️ https://t.co/bbESMcgsF7 🌍 https://t.co/Nrd9Y5Nwiw 🧠 https://t.co/wOqUBpfgk2 Building apps & Elite Pro Investor on eToro: 9yrs & 28% CAGR, stocks only.
Maggie Barton 🐝 @maggiehbarton
245 Followers 658 Following Investor, artist, entrepreneur. Just be & create. 💗 Art linked below 👇👇👇
Rajat Mohindra @MohindraRajat
0 Followers 5 Following
Riya Bisht @b1shtream
1K Followers 5K Following accelerating biology using AI/computing @join_ef, neuromorphic @CeNSEatIISc, VC @Lvlupvc, @iiscbangalore,prev @Vicharak_In @CERN @BerkeleyLab, @ucberkeley
Peter Ottsjö @peterottsjo
4K Followers 2K Following Journalist covering biotech & AI (➡️ https://t.co/XGxbqDfhBa), longevity (➡️ https://t.co/z7HYGJGlzh or @reachlevity). Reporter at Swedish tech outlet @nyteknik.
Noah Dinkin @imnoah
3K Followers 6K Following I'm Noah. Founder and CEO of @Stensul for the first decade, stay tuned for what’s next
Symplectic Manifold o... @MaxDiffusionRL
813 Followers 3K Following Likes surprisal. Wealth of weak ties. Eclectic af. Likes the unbenchmarked. Puts FEP/Hessians/Fisher info into their Claude prompt
Amanda Harris @_AmandaHarris
1K Followers 302 Following Credit by day. Happy place is where the wild things go #GoBlue #FindYourPark #ProtectPublicLands
Kushal Sinha, Ph.D. @sinkush
184 Followers 601 Following Scientist. Engineer. Innovator. Love hard problems that impacts society at large.
Shenzhen SamCome EcoT... @SamcomeEcoTech
13 Followers 65 Following SAMCOME a specialised manufacturer of high-performance bio-based materials and bioplastic processing machinery
Sumeet Singh @sumeet724
7K Followers 4K Following investing in worldbuilders 🌐 @browserbase @sfcompute @itsalltruffles @flowercomputers @cowboyspacecorp @interfere_ @actualinc prev @a16z
Arunabh Saxena @Arunabh85992578
211 Followers 4K Following Global TMT | DYOD BTech + Masters in EE from IIT Bombay
OmVenture @OmVenture
10K Followers 3K Following Peptides, proteomics, genomics, biotech, pharma for drugs, medical, prevention, diagnostics, healthcare & longevity using super intelligence automation ventures
Whoa @whoaboard
424 Followers 7K Following The whoa board makes things glow, it also makes glow-y things touch sensitive
Nathaniel Montana @scootermontana
487 Followers 950 Following
Anthropic @AnthropicAI
1.3M Followers 2 Following We're an AI safety and research company that builds reliable, interpretable, and steerable AI systems. Talk to our AI assistant @claudeai on https://t.co/FhDI3KQh0n.
Frank Gao @ChemVagabond
284 Followers 9 Following
Tamarind Bio @tamarindbio
1K Followers 1 Following Tamarind is a web app and API for the leading molecular design tools, trusted by tens of thousands of industry scientists including many global top 20 biopharma
Coefficient Bio @CoefficientBio
423 Followers 5 Following
BioRender @BioRender
29K Followers 2K Following The platform to create and collaborate on scientific figures, posters, graphs and more! Sign up free today
Odyssey Therapeutics @Odyssey_Tx
285 Followers 56 Following
Modal @modal
31K Followers 151 Following AI infrastructure that developers love 💚 Run inference, sandboxes, batch processing, training, and many other things on Modal
Sriram (Rami) Hathwar @hathwar607
366 Followers 723 Following Investor @_DimensionCap. Interested in ML infra and biotech!
Bauer LeSavage @bauer_lesavage
452 Followers 483 Following Research @_DimensionCap https://t.co/37u9sUBfRQ
Aspect Biosystems @aspectbiosys
2K Followers 762 Following Developing bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases.
Chai Discovery @chaidiscovery
6K Followers 4 Following
Monte Rosa Therapeuti... @MonteRosaTx
1K Followers 43 Following Monte Rosa Therapeutics is developing next-generation small molecule protein degraders to treat cancer and beyond.
Automata @automata_tech
1K Followers 270 Following A global biotech company providing robotic automation solutions to labs within the life sciences industry.
Simon Barnett @SimonDBarnett
3K Followers 2K Following Partner + Head of Research @_DimensionCap | Focused on the Intersection of Compute + Bio | Prev: Public Biotech Investor | Chemical Engineering @JohnsHopkins
NewLimit @newlimit
43K Followers 3 Following Working toward radical extension of human healthspan using epigenetic reprogramming.
Lamin @laminlabs
200 Followers 8 Following Open data framework for biology. Context and memory for datasets and models at scale.
Kaleidoscope.bio @kaleidoscopebio
204 Followers 7 Following Data infra and work orchestration for the the world’s most ambitious Life Science teams.
Enveda @lifeschemistry
2K Followers 94 Following Engineering new drugs from nature with knowledge graphs, metabolomics, and ML
























